Autifony Therapeutics initiates Phase I study of AUT00206, a novel treatment approach for schizophrenia

London – UK – 24th November 2015 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing loss and other serious brain disorders, today announced the start of Phase I clinical evaluation of its second Kv3 modulator, AUT00206. This is the first time that a Kv3 modulation mechanism has been applied to the treatment of schizophrenia. AUT00206 represents a novel class of Kv3 modulator which is being developed specifically for schizophrenia and related indications.

Read more (208 kB)